Evidence for eIF2α phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implications

por Krishnamoorthy, Jothilatha, Rajesh, Kamindla, Mirzajani, Farzaneh, Kesoglidou, Polixenia, Papadakis, Andreas I, Koromilas, Antonis E
Publicado 2014